Posted by on April 25, 2018 5:29 pm
Categories: Uncategorized

Source: CRISPR Technology Market, 2027 –

DUBLIN–()–The “Global
CRISPR Technology Market – Focus on Product, Applications, Geographical
Analysis, Industry Insights and Competitive Landscape – Analysis and
Forecast (2018-2027)”
report has been added to’s

Global CRISPR Technology Market Expected to Reach $10.55 Billion by 2027

The CRISPR technology industry is focused on the development of gene
therapeutics for the treatment of various genetic disorders such as
thalassemia, haemophilia, and sickle cell anaemia, among others. The
increasing prevalence of genetic disorders is promoting the growth of
the CRISPR technology, for better treatment and improved quality of life
of patients.

The CRISPR technology include designing tools, library, control kits,
plasmids, vectors, proteins, gRNA and other products to perform the
desired experiment and study the obtained results. Currently, CRISPR
technology is considered a valuable tool for the biotechnology and
biopharmaceutical companies to conduct cost effective and highly
efficient genome editing procedures. Moreover, advancements of CRISPR
technology reduced turn-around time and complexity of genome editing

The CRISPR technology provides several opportunities to develop the
one-time treatment for various rare genetic disorders. The
pharmaceutical industry is witnessing the growth of pipeline of
candidates developed using CRISPR technology. Several biopharmaceutical
companies are now indulging in the research and development of such
CRISPR based therapies. Furthermore, the advent of genome editing
technologies in molecular research has enabled the companies to target
the root cause of genetic and chronic diseases, with one-time procedure
and develop gene therapeutics to remain competitive in the market.

The purpose of this study is to gain a holistic view of the CRISPR
technology market in terms of various influencing factors, such as
recent trends, regulatory requirements, and technological advancements
of the market. The scope of this report constitutes a detailed study of
the products associated with the global CRISPR technology market, across
different regions. The market has been segmented into product’,
application’, and regions’. The report presents the reader with an
opportunity to unlock comprehensive insights with respect to the market
and helps in forming well-informed strategic decisions. The research
uncovers some of the substantial parameters that must be taken into
consideration before entering into the market.

This research report aims at answering various aspects of the global
CRISPR technology market with the help of the key factors driving the
market, restraints and challenges that can possibly inhibit the overall
market growth, and the current growth opportunities that are going to
shape the future trajectory of the market expansion.

The report includes an in-depth examination of the key players and
recent developments taking place in this market. Moreover, the report
includes chapters on market dynamics (market drivers, opportunities and
challenges) and industry analysis as well.

Key Topics Covered:

1 Market Overview

2 Market Dynamics

3 Competitive Landscape

4 Industry Insights

5 Global CRISPR Technology Market, by Product

6 Global CRISPR Technology Market, by Application

7 Global CRISPR Technology Market, by Region

8 Company Profiles

9 Report Scope & Methodology

Companies Mentioned

  • Agilent Technologies, Inc.
  • Applied StemCell, Inc.
  • Cellecta, Inc.
  • Corporate Summary
  • Dharmacon, Inc.
  • DiaCarta, Inc.
  • EdiGene, Inc.
  • GeneCopoeia, Inc.
  • GeneScript
  • Genedata AG
  • Global Presence
  • Integrated DNA Technologies (IDT), Inc.
  • Mirus Bio LLC
  • New England Biolabs
  • OriGene Technologies, Inc.
  • Oxford Genetics Ltd.
  • Rockland Immunochemicals, Inc.
  • Sigma Aldrich Corporation (A Subsidiary of Merck KGaA)
  • Synthego Corporation
  • System Biosciences, LLC
  • Takara Bio USA Inc. (A Subsidiary of Takara Bio Inc.)
  • Thermo Fisher Scientific Inc.
  • Transposagen Biopharmaceuticals
  • TransOMIC technologies inc.

For more information about this report visit

Published at Wed, 25 Apr 2018 10:17:00 +0000

Leave a Reply